Skip to content

Discontinued — last reported Q1 '26

Gross Profit at other companies

Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
$15K-98.9%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$21.49M-24.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
$281K-96.1%
GeneDx Holdings logo
GeneDx HoldingsWGS
$68.21M+16.6%
Guardant Health logo
Guardant HealthGH
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Calculated from Lucid Diagnostics’s reported figures.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's gross profit?
Lucid Diagnostics (LUCD) reported gross profit of -$369K in Q1 2026.
How has Lucid Diagnostics's gross profit changed year-over-year?
Lucid Diagnostics's gross profit increased by 49.0% year-over-year, from -$723K to -$369K.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.